NASDAQ:AUPH Aurinia Pharmaceuticals Q3 2026 Earnings Report $16.01 +0.32 (+2.04%) Closing price 04:00 PM EasternExtended Trading$15.98 -0.03 (-0.20%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aurinia Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.22Beat/MissN/AOne Year Ago EPSN/AAurinia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$83.61 millionBeat/MissN/AYoY Revenue GrowthN/AAurinia Pharmaceuticals Announcement DetailsQuarterQ3 2026Date11/3/2026TimeBefore Market OpensConference Call DateTuesday, November 3, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Aurinia Pharmaceuticals Earnings HeadlinesTG Therapeutics (NASDAQ:TGTX) vs. Aurinia Pharmaceuticals (NASDAQ:AUPH) Head to Head ContrastSeptember 30, 2026 | americanbankingnews.comAurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Has Average Target Price of $17.67September 28, 2026 | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 7 at 1:00 AM | Investors Alley (Ad)Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?August 28, 2026 | finance.yahoo.comAUPH stock rallies 6% after-hours — here’s whyAugust 19, 2026 | msn.comAurinia Settles Patent Litigation with TevaAugust 19, 2026 | financialpost.comFSee More Aurinia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email. Email Address About Aurinia PharmaceuticalsAurinia Pharmaceuticals (NASDAQ:AUPH). is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Lupkynis was approved by the U.S. Food and Drug Administration in 2021 and subsequently authorized in Canada. Aurinia markets the therapy primarily in North America and supports patients through commercial, medical, and patient-assistance programs. The company has also conducted research into additional autoimmune and kidney-related applications for its technology. Headquartered in Edmonton, Alberta, Aurinia was formerly known as Isotechnika Pharma before adopting its current name in 2013. The company has operated as a publicly traded biotechnology business focused on advancing treatments for patients with significant unmet medical needs.View Aurinia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
